NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Clinical trials for NON-MUSCLE INVASIVE BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New bladder cancer drug delivered straight to the tumor shows promise in early trial
Disease control Recruiting nowThis study tests a drug called erdafitinib, which is placed directly into the bladder using a special delivery system. The goal is to find the best dose and see if it can shrink or control bladder cancer that hasn't spread deeply into the bladder wall. About 235 people with non-m…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 23, 2026 21:18 UTC
-
New targeted therapy aims to keep bladder cancer from returning
Disease control Recruiting nowThis study tests a new treatment called TAR-210 (a drug placed directly into the bladder) against standard chemotherapy for people with a high-risk type of bladder cancer that has certain genetic changes. Participants must have already received BCG therapy. The goal is to see if …
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
Laser-Activated drug targets bladder tumors in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with non-muscle-invasive bladder cancer. The drug is injected directly into the tumor, sometimes with a laser to activate it. The main goal is to see if this approach is safe and feasib…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New targeted therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThis study compares a new drug delivery system (TAR-210) that releases erdafitinib directly into the bladder versus standard chemotherapy for people with intermediate-risk non-muscle invasive bladder cancer that has certain genetic changes (FGFR alterations). About 641 participan…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New bladder cancer treatment TAR-200 tested in Real-World study
Disease control Recruiting nowThis study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving TAR-200 treatment in everyday medical practice. The main goal is to measure how long the cancer stays away after starting TAR-200. Researchers will also track complete responses and side effec…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 01, 2026 17:54 UTC